DUBLIN, Ireland, March 3, 2014 (GLOBE NEWSWIRE) -- Prothena Corporation plc (Nasdaq:PRTA), a clinical stage biotechnology company focused on the discovery, development and commercialization of novel antibodies for the potential treatment of diseases that involve protein misfolding or cell adhesion, announced today the promotion of Tara Nickerson, PhD, MBA, to Chief Business Officer. Dr. Nickerson is responsible for leading corporate and business development, as well as alliance management efforts at Prothena. Prior to this appointment, Dr. Nickerson held the position of Head of Corporate and Business Development at Prothena, where she was instrumental during Prothena’s demerger from Elan Corporation Limited (formerly Elan Corporation, plc) and led the team that developed Prothena’s previously announced worldwide collaboration with Roche to develop and commercialize antibodies that target a-synuclein, including PRX002, Prothena’s monoclonal antibody for the treatment of Parkinson’s disease and other related synucleinopathies.
Help employers find you! Check out all the jobs and post your resume.
